Recruiting studies: Pik3Ca Mutations

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer
Phase 3 · 338 location(s) · Eli Lilly and Company · NCT07174336 A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors
Phase 1 · 4 location(s) · Cogent Biosciences, Inc. · NCT07383506 First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tu
Phase 1 · 37 location(s) · Relay Therapeutics, Inc. · NCT05216432 Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.
Phase 2/Phase 3 · 60 location(s) · Novartis Pharmaceuticals · NCT05948943 Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer
Phase 1/Phase 2 · 10 location(s) · SynDevRx, Inc. · NCT05455619 First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Parti
Phase 1/Phase 2 · 65 location(s) · Eli Lilly and Company · NCT05768139 A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R
Phase 2 · 49 location(s) · Hoffmann-La Roche · NCT07405801 Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PI
Phase 3 · 211 location(s) · Relay Therapeutics, Inc. · NCT06982521 Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
Phase 1/Phase 2 · 15 location(s) · Ensem Therapeutics · NCT06993844 A Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular Malformations
Phase 2 · 2 location(s) · Murdoch Childrens Research Institute · NCT05983159 Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With A
Phase 2 · 18 location(s) · Faeth Therapeutics · NCT06463028 Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormon
Phase N/A · 24 location(s) · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · NCT06805812 A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spe
Phase 2 · 34 location(s) · Relay Therapeutics, Inc. · NCT06789913 Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Canc
Phase 1/Phase 2 · 7 location(s) · Faeth Therapeutics · NCT07558733 Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors
Phase 1 · 5 location(s) · Regor Pharmaceuticals Inc. · NCT07524322 A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors
Phase 1 · 50 location(s) · Eli Lilly and Company · NCT05307705

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.